Patient receiving care in a clinical setting
Get in Touch

Contact Us

Contact Us

Let's talk.

Questions about BMX-001, our clinical programs, or partnering with BioMimetix? Send us a message and a member of our team will respond directly.

Send a Message

BioMimetix

A clinical-stage oncology company developing BMX-001, a first-in-class manganese porphyrin. Preclinically, BMX-001 enhances tumor response to radiation and chemotherapy while protecting normal tissue; clinically, it has demonstrated encouraging survival, normal-tissue protection, tolerability, and function across clinical programs.

© 2026 BioMimetix, Inc. All rights reserved.

Non-Confidential

BMX-001 is an investigational product candidate and is not approved by the FDA, EMA, or any other regulatory authority. Information on this website includes forward-looking statements and is provided for informational purposes only. See Legal & Disclaimers.